Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its board of directors will hold a meeting on April 29, 2025, to consider and approve the company’s first quarterly results for the period ending March 31, 2025. This meeting and subsequent publication of results could provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder interests.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development, manufacture, and sale of pharmaceutical products and healthcare services.
YTD Price Performance: 10.51%
Average Trading Volume: 5,648
Technical Sentiment Signal: Sell
Current Market Cap: $7.88B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue